Outpatient follow-up for patients with rheumatoid arthritis in relation to New Zealand Rheumatology Association guidelines at Dunedin Hospital

New Zealand Medical Journal

Volumn 121, Issue 1274, 2008, Pages 34-41

  Chan, Georgina ^a   Goh, Fern ^b   Hodgson, Timothy ^c   Hsu, Erica ^a   Johnstone, Deborah ^c   Ly, Jasen ^b   Platt, Timothy ^d   Rodrigues, Edrich ^e   Tsai, Wendy ^f   Hider, Phil ^g   Gray, Andrew ^g   Highton, John ^g  

^a Timaru Hospital   (New Zealand)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

^c WHANGAREI HOSPITAL   (New Zealand)

^d PORT MACQUARIE BASE HOSPITAL   (Australia)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

^f PALMERSTON NORTH HOSPITAL   (New Zealand)

^g UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT; IMMUNOLOGIC FACTOR;

ADD ON THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG RESPONSE; FEMALE; FOLLOW UP; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MEDICAL SOCIETY; MEDICAL SPECIALIST; NEW ZEALAND; OUTPATIENT CARE; PATIENT ASSESSMENT; PATIENT MONITORING; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; QUALITY CONTROL; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; AMBULATORY CARE; DISABILITY; DUTY TO RECONTACT; EPIDEMIOLOGY; ETHICS; MEDICAL ETHICS; MIDDLE AGED; STATISTICS;

AGED; AMBULATORY CARE; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISABILITY EVALUATION; DUTY TO RECONTACT; ETHICS, MEDICAL; FEMALE; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; NEW ZEALAND; PRACTICE GUIDELINES AS TOPIC;

EID: 45149133934     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Luqmani R, Hennell S, Estrach C, et al. British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Rheumatoid Arthritis (The first 2 years). Rheumatology. 2006;45(9):1167-9.
2. Breedveld F, Weisman M, Kavanaugh A, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis and Rheumatism. 2006;54(1):26-37.
3. Walsh D, Kelly C, Bosworth A, et al. Provisional guidelines for applying the Department of Health (England) 18-week-patient pathways to specialist rheumatology care. Rheumatology. 2007;46:1200-06.
4. Harrison A. Provision of rheumatology services in New Zealand. N Z Med J. 2004;117(1192). http://www.nzma.org.nz./journal/117-192/846
5. Balmer P, Theis J, McPhail J. Activity Plan Rheumatology 2006-7. Dunedin: Dunedin Public Hospital; 2006:33.
6. Alamanos Y, Voulgari P, Drosos A. Incidence and Prevalence of Rheumatoid Arthritis, Based on the 1987 American College of Rheumatology Criteria: A Systematic Review. Seminars in Arthritis and Rheumatism. 2006;36(3):182-8.
7. Anonymous. New Zealand Census. 2006, Wellington: Statistics New Zealand; 2006.
8. NZRA statement on follow-up intervals for Rheumatology Outpatients. 2004. http://www.rheumatology.org.nz/members/NZ16144.htm
9. de Jong Z, van der Heijde D, McKenna S, Whalley D. The reliability and construct validity of the RAQoL: A rheumatoid arthritis-specific quality of life instrument. British Journal of Rheumatology. 1997;36(8):878-83.
10. Tijhuis J, de Jong Z, Zwinderman A, et al. The validity of the Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire. Rheumatology. 2001;40(10):1112-9.